S. Tendolkar
About
S. Tendolkar is a scholar working on Infectious Diseases, Epidemiology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, S. Tendolkar has authored 46 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Infectious Diseases, 34 papers in Epidemiology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Tendolkar's work include Antifungal resistance and susceptibility (42 papers), Fungal Infections and Studies (31 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). S. Tendolkar is often cited by papers focused on Antifungal resistance and susceptibility (42 papers), Fungal Infections and Studies (31 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). S. Tendolkar collaborates with scholars based in United States and Australia. S. Tendolkar's co-authors include Daniel J. Diekema, L. Boyken, Michael A. Pfaller, S. A. Messer, R. J. Hollis, J. Kroeger, C. Rice, Gary V. Doern, Jennifer S. McDanel and Fathollah Riahi and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.
In The Last Decade
S. Tendolkar
45 papers receiving 3.2k citations
Peers
S. Tendolkar
L. Boyken United States
Alicia Gómez‐López Spain
Sharon C.-A. Chen Australia
Gloria M. González Mexico
Vidmantas Petraitis United States
Cheshta Sharma India
Ana Espinel-Ingroff United States
Caroline B. Moore United Kingdom
Erja Chryssanthou Sweden
Estrella Martín‐Mazuelos Spain
Citations per year, relative to S. Tendolkar S. Tendolkar (= 1×)
peers
L. Boyken
Countries citing papers authored by S. Tendolkar
Since
Specialization
Citations
This map shows the geographic impact of S. Tendolkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Tendolkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Tendolkar more than expected).
Fields of papers citing papers by S. Tendolkar
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by S. Tendolkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Tendolkar. The network helps show where S. Tendolkar may publish in the future.
Co-authorship network of co-authors of S. Tendolkar
This figure shows the co-authorship network connecting the top 25 collaborators of S. Tendolkar. A scholar is included among the top collaborators of S. Tendolkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Tendolkar. S. Tendolkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Diekema, Daniel J., Sandra S. Richter, Kristopher P. Heilmann, et al.. (2014). Continued Emergence of USA300 Methicillin-ResistantStaphylococcus aureusin the United States: Results from a Nationwide Surveillance Study. Infection Control and Hospital Epidemiology. 35(3). 285–292.
2.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2011). Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program. Journal of Clinical Microbiology. 49(4). 1274–1279.
3.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2010). Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagnostic Microbiology and Infectious Disease. 67(1). 56–60.
4.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2009). Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagnostic Microbiology and Infectious Disease. 65(1). 27–34.
5.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2009). Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp. Journal of Clinical Microbiology. 48(1). 52–56.
6.
Pfaller, Michael A., S. A. Messer, L. Boyken, et al.. (2008). In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species. Journal of Clinical Microbiology. 46(8). 2568–2572.
7.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2008). Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program. Journal of Clinical Microbiology. 46(11). 3585–3590.
8.
Huang, Susan S., Daniel J. Diekema, David K. Warren, et al.. (2008). Strain‐Relatedness of Methicillin‐ResistantStaphylococcus aureusIsolates Recovered from Patients with Repeated Infection. Clinical Infectious Diseases. 46(8). 1241–1247.
9.
Diekema, Daniel J., S. A. Messer, R. J. Hollis, et al.. (2008). A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.. Diagnostic Microbiology and Infectious Disease. 63(2). 233–236.
10.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. Journal of Clinical Microbiology. 46(9). 3184–3185.
11.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2007). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. Journal of Clinical Microbiology. 46(1). 150–156.
12.
Messer, S. A., Daniel J. Diekema, L. Boyken, et al.. (2006). Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp. Journal of Clinical Microbiology. 44(2). 324–326.
13.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance. Journal of Clinical Microbiology. 44(3). 760–763.
14.
Pfaller, Michael A., S. A. Messer, L. Boyken, et al.. (2006). Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods. Journal of Clinical Microbiology. 45(1). 70–75.
15.
Pfaller, Michael A., L. Boyken, S. A. Messer, et al.. (2005). Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. Journal of Clinical Microbiology. 43(10). 5208–5213.
16.
Pfaller, Michael A., S. A. Messer, L. Boyken, et al.. (2005). Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004). Journal of Clinical Microbiology. 43(5). 2163–2167.
17.
Pfaller, Michael A., Daniel J. Diekema, L. Boyken, et al.. (2005). Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis. Antimicrobial Agents and Chemotherapy. 49(11). 4795–4797.
18.
Pfaller, Michael A., L. Boyken, R. J. Hollis, et al.. (2004). Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. Diagnostic Microbiology and Infectious Disease. 50(2). 113–117.
19.
Pfaller, Michael A., S. A. Messer, L. Boyken, et al.. (2004). In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagnostic Microbiology and Infectious Disease. 48(3). 201–205.
20.
Pfaller, Michael A., S. A. Messer, L. Boyken, et al.. (2004). Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole. Journal of Clinical Microbiology. 42(1). 380–383.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by L. Boyken Breakdown of academic impact, for papers by Alicia Gómez‐López Breakdown of academic impact, for papers by Sharon C.-A. Chen Breakdown of academic impact, for papers by Gloria M. González Breakdown of academic impact, for papers by Vidmantas Petraitis Breakdown of academic impact, for papers by Cheshta Sharma Breakdown of academic impact, for papers by Ana Espinel-Ingroff Breakdown of academic impact, for papers by Caroline B. Moore Breakdown of academic impact, for papers by Erja Chryssanthou Breakdown of academic impact, for papers by Estrella Martín‐Mazuelos